Cargando…
The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after rep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366089/ https://www.ncbi.nlm.nih.gov/pubmed/34212527 http://dx.doi.org/10.1002/cam4.4102 |
_version_ | 1783738839071719424 |
---|---|
author | Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping |
author_facet | Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping |
author_sort | Chen, Zhi‐Yuan |
collection | PubMed |
description | BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA). METHODS: From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated. RESULTS: There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05). CONCLUSIONS: The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR. |
format | Online Article Text |
id | pubmed-8366089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83660892021-08-23 The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping Cancer Med Clinical Cancer Research BACKGROUND: The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA). METHODS: From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated. RESULTS: There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05). CONCLUSIONS: The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR. John Wiley and Sons Inc. 2021-07-01 /pmc/articles/PMC8366089/ /pubmed/34212527 http://dx.doi.org/10.1002/cam4.4102 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title_full | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title_fullStr | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title_full_unstemmed | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title_short | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
title_sort | predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366089/ https://www.ncbi.nlm.nih.gov/pubmed/34212527 http://dx.doi.org/10.1002/cam4.4102 |
work_keys_str_mv | AT chenzhiyuan thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT guozhixing thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT lulianghe thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT meijie thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT linwenping thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT lishaohua thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT weiwei thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT guorongping thepredictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT chenzhiyuan predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT guozhixing predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT lulianghe predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT meijie predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT linwenping predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT lishaohua predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT weiwei predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma AT guorongping predictivevalueofvesselsencapsulatingtumorclustersintreatmentoptimizationforrecurrentearlystagehepatocellularcarcinoma |